Table 2.

Clinical trials of vaccine efficacy and post-introduction evaluations of vaccine effectiveness for prevention of moderate-to-severe rotavirus diarrhea in African countries.

Country	Study type	Vaccine	Vaccine effectiveness mean (95% CI)	Reference
Lower child mortality rate group (<67 deaths per 1000 live births)
Botswana	Effectiveness, post-introduction	Rotarix	54% (23–73)	Gastañaduy [35]
Kenya	Efficacy, clinical trial	RotaTeq	64% (−6–90)	Armah [9]
Rwanda	Effectiveness, post-introduction	RotaTeq	80% (28–94)	Ngabo [36]
South Africa	Effectiveness, post-introduction	Rotarix	57% (40–68)	Groome [37]
South Africa	Efficacy, clinical trial	Rotarix	77% (56–88)	Madhi [8]
Tanzania	Effectiveness, post-introduction	Rotarix	57% (14–78)	Abeid [38]
Higher child mortality rate group (≥67 deaths per 1000 live births)
Ghana	Effectiveness, post-introduction	Rotarix	18% (−81–63)	Armah [39]
Ghana	Efficacy, clinical trial	RotaTeq	56% (28–73)	Armah [9]
Malawi	Effectiveness, post-introduction	Rotarix	64% (24–83)	Bar Zeev [40]
Malawi	Effectiveness, post-introduction	Rotarix	58% (20–78)	Bar Zeev [26]
Malawi	Efficacy, clinical trial	Rotarix	49% (19–68)	Madhi [8]
Mali	Efficacy, clinical trial	RotaTeq	18% (−23–45)	Armah [9]
Zambia	Effectiveness, post-introduction	Rotarix	56% (−34–86)	Beres [41]